Samsara BioCapital, LLC — 13F Holdings & Portfolio
CIK 1744967 · latest 13F-HR filed 2026-05-15
Samsara BioCapital, LLC manages $1.03B in 13F-reported U.S. long-equity assets across 22 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are SRRK (32.95%), MLYS (15.45%), ALMS (13.58%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 3 new positions, exited 2, added to 6, and trimmed 10.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.03B
Long-equity book
22
Distinct positions
2026-03-31
Filed 2026-05-15
+3 / −2 / ↑6 / ↓10
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALUMIS INC$83.6M +148.8%
- SCHOLAR ROCK HLDG CORP$35.2M +11.6%
- SUTRO BIOPHARMA INC$24.1M +1019.0%
- INVENTIVA SA$4.7M +19.4%
- ARCELLX INC$3.0M +76.1%
Top Trims
- MINERALYS THERAPEUTICS INC-$54.0M -25.4%
- KALARIS THERAPEUTICS INC-$34.6M -31.6%
- GOSSAMER BIO INC-$20.0M -89.4%
- UPSTREAM BIO INC-$13.4M -66.9%
- SEPTERNA INC-$12.1M -13.8%
New Positions
- SPYGLASS PHARMA INC$54.7M
- AGOMAB THERAPEUTICS NV$6.3M
- COHERUS ONCOLOGY INC$5.8M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $339.1M | 32.95% | 6,897,652 | SH |
| 2 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $159.0M | 15.45% | 5,871,018 | SH |
| 3 | ALUMIS INC | ALMS | 022307102 | $139.8M | 13.58% | 6,345,219 | SH |
| 4 | SEPTERNA INC | SEPN | 81734D104 | $75.7M | 7.35% | 3,149,128 | SH |
| 5 | KALARIS THERAPEUTICS INC | KLRS | 482929106 | $74.7M | 7.26% | 12,948,081 | SH |
| 6 | SPYGLASS PHARMA INC | SGP | 85220G109 | $54.7M | 5.31% | 2,109,953 | SH |
| 7 | NEUROGENE INC | NGNE | 64135M105 | $34.6M | 3.36% | 1,717,127 | SH |
| 8 | INVENTIVA SA | IVA | 46124U107 | $28.8M | 2.80% | 5,194,805 | SH |
| 9 | SUTRO BIOPHARMA INC | STRO | 869367201 | $26.5M | 2.57% | 1,062,872 | SH |
| 10 | JADE BIOSCIENCES INC | JBIO | 008064206 | $13.6M | 1.32% | 968,798 | SH |
| 11 | VTV THERAPEUTICS INC | VTVT | 918385204 | $11.8M | 1.15% | 298,496 | SH |
| 12 | AQUESTIVE THERAPEUTICS INC | AQST | 03843E104 | $10.4M | 1.01% | 2,500,000 | SH |
| 13 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $7.6M | 0.74% | 1,832,566 | SH |
| 14 | NKARTA INC | NKTX | 65487U108 | $7.4M | 0.72% | 3,507,666 | SH |
| 15 | ARCELLX INC | ACLX | 03940C100 | $7.0M | 0.68% | 60,873 | SH |
| 16 | UPSTREAM BIO INC | UPB | 91678A107 | $6.6M | 0.64% | 736,047 | SH |
| 17 | ABIVAX SA | ABVX | 00370M103 | $6.3M | 0.61% | 56,581 | SH |
| 18 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $6.3M | 0.61% | 600,000 | SH |
| 19 | RANI THERAPEUTICS HLDGS INC | RANI | 753018100 | $6.2M | 0.61% | 8,500,000 | SH |
| 20 | COHERUS ONCOLOGY INC | CHRS | 19249H103 | $5.8M | 0.56% | 3,428,571 | SH |
| 21 | PALVELLA THERAPEUTICS INC NE | PVLA | 697947109 | $4.8M | 0.47% | 38,432 | SH |
| 22 | GOSSAMER BIO INC | GOSS | 38341P102 | $2.4M | 0.23% | 7,222,559 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $1.03B | 22 | 0001744967-26-000005 |
| 2025-12-31 | 2026-02-17 | $969.3M | 21 | 0001744967-26-000002 |
| 2025-09-30 | 2025-11-14 | $765.9M | 27 | 0001744967-25-000004 |